A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB

BACKGROUND: Treatment for TB is lengthy and toxic, and new regimens are needed.

Bibliographic Details
Main Authors:	Amukoye, E (Author), Balanag, V (Author), Ban, AYL (Author), Bateson, ALC (Author), Betteridge, MC (Author), Brumskine, W (Author), Caoili, J (Author), Cevik, M (Author), Chaisson, RE (Author), Conradie, F (Author), Crook, AM (Author), Dawson, R (Author), del Parigi, A (Author), Diacon, A (Author), Everitt, DE (Author), Fabiane, SM (Author), Gillespie, SH (Author), Hunt, R (Author), Ismail, AI (Author), Lalloo, U (Author), Lombard, L (Author), Louw, C (Author), Malahleha, M (Author), McHugh, TD (Author), Mendel, CM (Author), Mhimbira, F (Author), Moodliar, RN (Author), Nduba, V (Author), Nunn, AJ (Author), Sabi, I (Author), Sebe, MA (Author), Selepe, RAP (Author), Spigelman, M (Author), Staples, S (Author), Swindells, S (Author), Tweed, CD (Author), van Niekerk, CH (Author), Variava, E (Author), Wills, GH (Author)
Format:	Article
Language:	English
Published:	2021
Subjects:	ANTITUBERCULOSIS TREATMENT DRUG drug resistance PA-824 SAFETY TB treat-ment TB-HIV tuberculosis
Online Access:	View Fulltext in Publisher

View Fulltext in Publisher

Similar Items